On Friday, October 9, 2020, Fibrolamellar Cancer Foundation’s John Hopper accepted a 2020 National Organization of Rare Diseases (NORD) Rare Impact Award on behalf of the Rare Cancer Coalition (RCC).  This award, the Abbey S Meyer Leadership Award, is one of the highest honors bestowed by NORD for programs that address awareness, education and research funding needs for often ignored cancers, like fibrolamellar. 

The Fibrolamellar Cancer Foundation played a key role in the formation of NORD’s Rare Cancer Coalition. Created in 2017, NORD’s Rare Cancer Coalition (RCC) aims to unite NORD Member Organizations working in rare cancers to collaborate on issues facing the greater rare cancer community. The coalition strengthens its individual members through capacity building, networking and peer-to-peer mentoring. Currently RCC includes over 25 rare cancer foundations across the globe with support from the NCI, FDA, industry and academia.  

RCC Co-Chairmen, Jim Palma, Executive Director of the TargetCancer Foundation, and John Hopper, President of the Fibrolamellar Cancer Foundation received the award on behalf of the RCC.

The proceedings can be viewed below in this excerpt from the award event: